Condition: Primary Central Nervous System Hodgkin Lymphoma · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
This phase II trial is evaluating the efficacy and side effect of orelabrutinib, sintilimab and temozolomide as possible treatments for relapsed or refractory central nervous system lymphoma.
This description comes directly from the study's public registry record.
Wenbin Qian, Prof. · +8613605801032 · qianwb@zju.edu.cn
Xianggui Yuan, Dr. · +8613989883884 · yuanxg@zju.edu.cn
Always discuss trial participation with your own doctor first.
| 2nd Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04961515